A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Scholars discuss the regulatory landscape surrounding GLP-1 drugs and dietary supplements.

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

A registered dietitian reveals nine food that work like weight-loss drugs, helping to curb cravings and suppress your ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Tirzepatide demonstrated sustained average weight loss of Eli Lilly ... Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for ...